NCT00530309已完成1 期
Clinical Assessment of GSK716155 for Type 2 Diabetes Mellitus -A Phase I/II Study to Investigate the Safety, Pharmacokinetics and Pharmacodynamics of GSK716155 in Japanese Subjects With Type 2 Diabetes Mellitus
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 40
- 试验地点
- 1
- 主要终点
- Plasma concentrations and PD parameters over time and at the end of study
研究概览
简要总结
A Phase I/II study to investigate the safety, pharmacokinetics and pharmacodynamics of GSK716155 in Japanese subjects with type 2 diabetes mellitus
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
入排标准
- 年龄范围
- 20 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究组 & 干预措施
Subjects receiving GSK716155 + placebo
Experimental
Eligible subjects will receive GSK716155 with doses of 15 milligrams once a week, 30 milligrams once a week, 50 milligrams biweekly or 100 milligrams once every four weeks. Subjects will also receive placebo.
干预措施: GSK716155 for injection (Drug)
Subjects receiving GSK716155 + placebo
Experimental
Eligible subjects will receive GSK716155 with doses of 15 milligrams once a week, 30 milligrams once a week, 50 milligrams biweekly or 100 milligrams once every four weeks. Subjects will also receive placebo.
干预措施: Placebo (Drug)
结局指标
主要结局
Plasma concentrations and PD parameters over time and at the end of study
时间窗: Up to Week 9
次要结局
- Other metabolic parameters at the end of study(Up to Week 9)
研究者
研究点 (1)
Loading locations...
相似试验
终止
2 期
MK0767 in Type 2 Diabetes (0767-012)Type 2 Diabetes MellitusNCT00543556Merck Sharp & Dohme LLC514
已完成
2 期
A Study in Type 2 Diabetics of Single and Multiple Doses of Orally Administered GSK1292263 to Investigate the Safety, Tolerability, Pharmacokinetics and PharmacodynamicsDiabetes Mellitus, Type 2NCT01119846GlaxoSmithKline100
终止
1 期
Safety, Clinical Activity, Pharmacokinetics (PK) and Pharmacodynamics Study of GSK2879552, Alone or With Azacitidine, in Subjects With High Risk Myelodysplastic Syndromes (MDS)Myelodysplastic SyndromesMyelodysplastic SyndromeNCT02929498GlaxoSmithKline7
招募中
1 期
Assessing Pharmacokinetics and Pharmacodynamics of Daily Enteric-coated Aspirin in Patients With StablE Diabetes IIPlatelet AggregationAspirinPlatelet Aggregation InhibitorsType 2 DiabetesDiabetes Mellitus, Type 2NCT05702463Montreal Heart Institute30
进行中（未招募）
早期 1 期
Assessing Pharmacokinetics and Pharmacodynamics of Daily Enteric-coated Aspirin in Patients With StablE DiabetesDiabetes Mellitus, Type 2NCT05105919Montreal Heart Institute50